Predicting cognitive deficits in people with Parkinson's disease

June 20, 2017
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Parkinson's disease (PD) is commonly thought of as a movement disorder, but after years of living with PD approximately twenty five percent of patients also experience deficits in cognition that impair function. A newly developed research tool may help predict a patient's risk for developing dementia and could enable clinical trials aimed at finding treatments to prevent the cognitive effects of the disease. The research was published in Lancet Neurology and was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

"By allowing clinical researchers to identify and select only patients at high risk for developing dementia, this tool could help in the design of 'smarter' trials that require a manageable number of participating patients," said corresponding author Clemens Scherzer, MD, head of the Neurogenomics Lab and Parkinson Personalized Medicine Program at Harvard Medical School and a member of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital.

For the study, the research team combined data from 3,200 people with PD, representing more than 25,000 individual clinical assessments and evaluated seven known clinical and associated with developing dementia. From this information, they built a computer-based risk calculator that may predict the chance that an individual with PD will develop cognitive deficits.

"This study includes both genetic and clinical assessments from multiple groups of patients, and it represents a significant step forward in our ability to effectively model one of the most troublesome non-motor aspects of Parkinson's disease," said Margaret Sutherland, PhD, program director at the NINDS.

Currently available medications are effective in improving motor deficits caused by the disease. However, the loss of cognitive abilities severely affects an individual's quality of life and independence. One barrier to developing treatments for the of PD is the considerable variability among patients. As a result, researchers must enroll several hundred patients when designing to test treatments.

Scherzer and team also noted that a patient's education appeared to have a powerful impact on the risk of memory loss. The more years of formal education patients in the study had, the greater was their protection against cognitive decline.

"This fits with the theory that education might provide your brain with a 'cognitive reserve,' which is the capacity to potentially compensate for some of the disease-related effects," said Scherzer. "I hope researchers will take a closer look at this. It would be amazing, if this simple observation could be turned into a useful therapeutic intervention."

Moving forward, Scherzer and his colleagues from the International Genetics of Parkinson's Disease Progression (IGPP) Consortium plan to further improve the cognitive risk score calculator. The team is scanning the genome of PD patients to hunt for new progression genes. Ultimately, it is their hope that the tool can be used in the clinic in addition to helping with clinical trial design. However, considerable research remains to be done before that will be possible.

One complication for the use of this calculator in the clinic is the lack of available treatments for PD-related cognitive deficits. Doctors face ethical issues concerning whether patients should be informed of their risk when there is little available to help them. It is hoped that by improving , the risk calculator can first aid in the discovery of new PD treatments and determine which would benefit most from the new treatments.

"Prediction is the first step," said Scherzer. "Prevention is the ultimate goal, preventing a dismal prognosis from ever happening."

Explore further: Parkinson's disease and cognitive decline—a genetic connection revealed

More information: Liu et al. "Prediction of cognition in Parkinson's disease with a clinical-genetic score: longitudinal analysis of nine cohorts." Lancet Neurology DOI: 10.1016/S1474-4422

Related Stories

Parkinson's disease and cognitive decline—a genetic connection revealed

December 1, 2016
Although the hallmark symptoms of Parkinson's disease (PD) – such as involuntary shaking, slowness of movement and muscle rigidity – are related to movement, recent evidence has suggested that memory impairment plays ...

Researchers identify biomarkers that may predict cognitive impairment

May 17, 2017
New biomarkers identified by a research team in the Perelman School of Medicine at the University of Pennsylvania could help predict which Parkinson's disease patients will suffer significant cognitive deficits within the ...

Trial helps doctors tell Lewy body dementia from Alzheimer's, Parkinson's

September 21, 2016
Knowing that many clinicians find it difficult to correctly diagnose patients with Lewy body dementia, researchers at The Ohio State University Wexner Medical Center set out to develop a clinical profile for these patients. ...

Researchers identify biomarker for early cognitive decline in Parkinson's disease patients

February 17, 2016
Many patients with Parkinson's Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing ...

Finding a treatment for Parkinson's disease dementia

September 2, 2015
University of Adelaide neuroscientists are leading a world-first study into a form of dementia experienced by many Parkinson's disease suffers, which is expected to ultimately lead to a new therapy for the condition.

New effort to identify Parkinson's biomarkers

March 5, 2013
Last month, the National Institutes of Health announced a new collaborative initiative that aims to accelerate the search for biomarkers—changes in the body that can be used to predict, diagnose or monitor a disease—in ...

Recommended for you

Researchers find new path to promising Parkinson's treatment

September 19, 2017
Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

Medical history can point to earlier Parkinson's disease diagnosis

September 15, 2017
Before symptoms become pronounced, there is no reliable way to identify who is on track to develop Parkinson's disease, a debilitating movement disorder characterized by tremors, slowness of movement, stiffness, and difficulty ...

Brain rewiring in Parkinson's disease may contribute to abnormal movement

September 14, 2017
The brain's own mechanisms for dealing with the loss of dopamine neurons in Parkinson's disease may be a source of the disorder's abnormal movement, according to a Northwestern Medicine study published in Neuron.

Treating with antioxidants early in Parkinson's disease process may halt degeneration and improve neuronal function

September 7, 2017
Northwestern Medicine scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson's disease (PD) and figured out how to interrupt it, reports a study to be published September ...

New diagnostic tool spots first signs of Parkinson's disease

September 6, 2017
Researchers have developed the first tool that can diagnose Parkinson's disease when there are no physical symptoms, offering hope for more effective treatment of the condition.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.